M
any bench scientists are just too caught up in their research to consider its ethical possibilities, and very few want to take the time to rigorously explore them. However, the controversy over the research into the genetic modification of the H5N1 flu virus, finally approved for publication, should offer a reminder of the importance of debate. Conversations about dual-use technology -work that could be used for both humanitarian and unethical ends -should go way beyond mutant flu. On page 432 of this issue, we discuss broader case studies and show the need for reflection and discussion in many areas of science.
'Dual-use technology' is not a synonym for science, of course -a simple knife can be a tool or a weapon, whereas research into turtle navigation will not yield long-range missile technology, for example. But dual-use basic research is a special case because its implications, for good and bad, are often viewed with the greatest clarity by only a small minority of people. The scientists involved (and they are increasingly specialists in very small fields) are often the only ones that can fully understand the risks posed by a line of research.
Some fields have structures in place to ensure scrutiny from outside, yet, too often, scientists are slow to raise their hands with uncomfortable questions. Why? Some may feel that speaking frankly and drawing attention to dangers, real or perceived, will cause trouble for their labs, whereas others feel that they would be wasting time on what they regard as hypothetical conundrums. Optimism is also a factor: most researchers genuinely believe in the benefits of their work, and few want to think about the drawbacks.
There are disadvantages to leaving it up to outsiders to initiate debate about risks, benefits and ethics. The first is that in the early, fertile stages of public debate, some threats are easily underestimated whereas others are overestimated. Everyone can understand the risk posed by a knife, but few are qualified to recognize the dangers of using lasers to enrich nuclear isotopes. And misconceptions are rife: many members of the public believe that neuroscientists have already made mind-reading possible, even though fundamental research into predicting a subject's intent has only just begun.
The second risk is that non-scientists can take control of the debate, especially when concerns about science are expressed as surrogates for concerns about associated values and perceived benefit. For example, environmental groups made a strong public case against the use of genetically modified organisms in food, especially in Europe, even though most scientists who have studied the risk from such food say that it is vanishingly small.
Finally, there is the possibility that decisions about research will end up in the lap of a regulator that lacks either the knowledge or the authority to handle it. The US National Science Advisory Board for Biosecurity found itself effectively refereeing the publication of the controversial H5N1 papers. And in the Netherlands, legal arguments over whether the nation's export-control authorities have jurisdiction
"Researchers should publicly ask whether the work being done by their colleagues poses any threat."

Chase the dragon
A planned commercial trip to the space station shows a future direction for NASA. T he US space programme is trapped in a war between financial constraints and costly inertia. For decades, the political talk was that manned space flight would continue as it always had, or become even bolder and more inspiring. Last week's final flight of the space shuttle Discovery, piggy-backing on a jumbo jet on its way to a museum, showed the reality -the glory days of NASA, for now at least, are behind it.
Next month, the agency is scheduled to take a small but significant step towards a different future. Supplies for NASA's one remaining flagship piece of manned hardware, the International Space Station, will be packed into a capsule built and sent into orbit by a private firm -SpaceX of Hawthorne, California. 
Suckers for success
The use of leeches is making a comeback, and not just in medicine. I n the 1807 poem Resolution and Independence, William Wordsworth recalls a dawn encounter with a withered old man on a moor: "He told, that to these waters he had come | To gather leeches, being old and poor: | Employment hazardous and wearisome!" Nineteenth-century gatherers often dunked their legs into leechfilled bogs and ponds until the bloodsuckers began to feast. The motivation was money: medical use of leeches, or hirudotherapy, was at its height in Europe, and surgeons needed every leech they could get. France reportedly imported 42 million medicinal leeches in 1833 alone.
Leech therapy dates to ancient Greece, and perhaps earlier. Hippocrates preached the importance of balancing the four humours (blood, phlegm and black and yellow bile) through bloodletting. Because they secrete a host of enzymes to anaesthetize their victims at the spot of a bite and to keep the blood flowing, leeches were useful when drawing blood from sensitive parts of the body such as the mouth, larynx and anus.
Nicander of Colophon, who lived in the second century BC, described the medical use of leeches, which belong to the same phylum (Annelida) as earthworms, in his poem Alexipharmaca. Greek, Roman and Arabic doctors embraced their use, and English doctors in the Middle Ages were often called leeches; the Anglo-Saxon word laece means healer.
The leech bubble burst in the second half of the nineteenth century, when people realized that the animals made most patients worse, not better. By 1879, London's leading leech importer was distributing just a tenth of the 30,000 or so it once had, and they "principally go to Scotland", the British Medical Journal noted that year.
Still, the leech has never really left the medical mind, and it is starting to be used again. Reconstructive surgery, always a hotbed of innovation, was the first field to re-embrace the medicinal leech (Hirudo spp.). A survey of the 62 plastic-surgery units in the United Kingdom and Republic of Ireland in 2002 found that 80% had used leeches in the past five years, with just four centres reporting that a patient had turned down hirudotherapy (I. S. Whitakera et al. Br. J. Plast. Surg. 57, 348-353; 2004) . No wonder. Leeches are thought to improve the outcomes of reattached digits, ears and other body parts by preventing veins from becoming clogged .
Leeches also ease the pain caused by osteoarthritis. Among the 30 or so biologically active substances in their saliva are molecules that stop inflammation and blood clotting, both of which are involved in arthritis.
Medical-grade-leech sales haven't returned to their early-nineteenthcentury heights, but the animals are once again selling briskly. Britain's largest supplier, Biopharm Leeches in Hendy, Wales (which has the tag line "The biting edge of science"), ships around 50,000 per year, and in 2004, a French firm, Ricarimpex in Eysines, won clearance from the US Food and Drug Administration to market its leeches as medical devices in the United States.
Leech use is not restricted to medicine. As we report on page 424, tropical leeches are being recruited in the search for endangered species. These leeches preserve DNA from the last mammal they fed on, so can offer clues to the mammal's range and location. Conservationists in Vietnam and Laos plan to scour the bellies of leeches in their search for the saola antelope (Pseudoryx nghetinhensis), one of the world's rarest animals.
It is a fitting twist for the medical leech, which itself is listed as a 'near threatened' species in the wild and may have been in decline even in Wordsworth's time. "Once I could meet with them on every side, " the old leech gatherer tells the young poet. "But they have dwindled long by slow decay; | Yet still I persevere, and find them where I may. " ■ Success is far from assured -a scheduled 30 April launch had been delayed as Nature went to press, and the testing schedule of the Falcon 9 launch rocket has been accelerated to accommodate the unmanned supply flight. But if the Dragon capsule does succeed in its mission to dock with the space station and then return to Earth, NASA will be optimistic that the craft could soon carry more than supplies. With the retirement of the shuttle, the agency lost its independent link to its space station, and must now rely on the Russian Soyuz system to launch new crews and bring its astronauts home again. A contract with SpaceX to send people into space in Dragon would restore some national pride, as well as reducing crucial dependence on the production and continued success of a foreign rocket. A Soyuz failure that saw the loss of astronauts would effectively close down the space station.
The impending launch of Dragon has brought conflicting reactions. Enthusiasts see a new frontier opening up for commercial operators at all levels, from suborbital research flights to full-on private hotels in space. In a World View article on page 417, Alan Stern, an unashamed enthusiast, explains how far private firms are determined to boldly go.
Then there are the curmudgeons, those who claim that the new model is a classic case of the emperor's new clothes. NASA has always relied on private companies to build its rockets and capsules, they point out, and is handing a huge subsidy to SpaceX. So this heralded new dawn is merely a reworded contract here and a shift in financial emphasis there. The dragon, they say, has no teeth.
The truth, as so often, is likely to fall somewhere in between. Although aerospace firms such as Lockheed and Boeing have always helped NASA to carry the stars and stripes aloft, they did so on a costplus basis, with the agency meeting all costs, however large the eventual bill, and then adding on a substantial and guaranteed profit. If Dragon shows that the private sector can do more on its own terms -from design to sourcing component parts -then the costs will come down. Scientists should welcome the move. The further NASA can get from the cost-plus contracts of the past, and the nearer to buying room on a rocket as a commodity -similar to seats on a commercial airliner -the better. NASA could then spend more of its money on the things to be launched, people and probes, rather than on rocket launches that remain as expensive as they have always been.
And as the News story on page 426 shows, the planned launch of Dragon -and its ability to bring back scientific samples under controlled conditions -is already raising hopes in the space-science community that the space station could finally begin to fulfil its potential for research.
There is strong precedent for the way the US government is trying to nurture the commercial space-flight business. In the early days of aeroplane flight, government officials handed out guaranteed contracts to aviation pioneers for carrying airmail. And in the 1970s, by both funding the developers of microchips and promising to buy the results, the US Department of Defense kick-started the computer industry.
The market for the services provided by SpaceX and its ilk is, of course, smaller. The space station is scheduled to operate -and so will need to be supplied -until only 2020. Contracts to launch satellites are lucrative, but the great unknown on the balance sheet remains the demand from scientists and from wealthy individuals willing to pay big money for tourist flights to space.
A successful SpaceX operation next month will not resolve such questions, but it would make more people ask them more seriously. And that can only be a good thing. ■ "The great unknown remains the demand from scientists and wealthy individuals willing to pay to access space."
